Tetsuya Yamagata
Company: Modalis Therapeutics
Job title: CSO
Seminars:
Counter-Balanced Immune Response Against Cas9-Mediated Epigenetic Modulation Induces Durable Therapeutic Efficacy 12:00 pm
Exploring dosage for gene editing Examining the efficacy of gene editing Reducing AAV immunogenicityRead more
day: Conference Day Two